Treats hypertension. ANDA 91541, held by Micro Labs. Losartan Potassium.
As of Nov 21, 2026, ANDA 91541 (Losartan Potassium), held by Micro Labs, was first approved by FDA on Sep 24, 2012, with 8 approved supplements and 0 published complete response letters.
Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 2012 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Discontinued |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Discontinued |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Discontinued |
| Apr 10, 2026 | Supplement 15Labeling · Standard review | Approved | None posted |
| Aug 23, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| May 7, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 9, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 7, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 5, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 11, 2013 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 31, 2013 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 24, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters